Andrew Nunn, Professor of Epidemiology, Medical Research Council Clinical Trials Unit at UCL, describes the first phase 3 trial of a shortened treatment for MDR-TB.
Led by Yale Cancer Center, new research shows that enfortumab vedotin is an effective alternative for patients with muscle-invasive bladder cancer (MIBC)
Research shows that T cells, created by the common cold, can give some protection against COVID - which means that universal vaccines can mimic this technology.